Wednesday, November 22, 2017
CLOSE
 
Fidson Healthcare Plc and GB Pharma Holdings position to expand pharmaceutical outreach into Nigeria and Beyond
By Sentinel News Service
Published February 4, 2016

INT - gb pharma1
Meeting at US Pharmacopeia: Dr. Estelle-Marie Heussen, COO GB Pharma Holdings; Dr. Fidelis Ayebae, CEO Fidson Healthcare; Dr. Gloria B. Herndon, CEO GB Pharma Holdings

The leading and publicly traded Nigerian pharmaceutical company, Fidson Healthcare Plc, has recently made a major leap toward addressing Nigeria’s pharmaceutical needs by entering into an agreement with the American company, GB Pharma Holdings. Their business agreement is expected to provide Fidson with the guidance it needs to establish its foothold within the US and to develop strategic relationships with other business entities (i.e., US Pharmacopeia [USP], Constituency for Africa, Presidential Emergency Plan for Aids Relief [PEPFAR], UNAIDS and Howard University, to name a few). Of them all, USP will be the most critical. It will insure Fidson’s growth by helping it sustain U.S. and international standards.

Founded in 1820, this scientific nonprofit organization will share with Fidson its expertise by overseeing the identity, strength, quality and purity of medicines, food ingredients and dietary supplements that Fidson will manufacture and distribute. Besides its strategic engagement with USP, Fidson is also positioning itself with PEPFAR and UNAIDS, in order to become a viable supplier/manufacturer of antiretroviral therapy for HIV positive patients within and outside of Nigeria. Relationships with organizations such as CFA and Howard University College of Pharmacy will aid Fidson at stretching its influence and spearheading its collaborative efforts to cover African-American/African Diaspora healthcare.

INT - gb pharma2
Visiting the New York Stock Exchange: Dr. Estelle- Marie Heussen, COO GB Pharma Holdings; Dr. Fidelis Ayebae, CEO Fidson Healthcare; Dr. Gloria B. Herndon, CEO GB Pharma Holdings

With the support of GB Pharma Holdings, Immune Therapeutics Incorporation [OTCQB: IMUN], and American Hospitals & Resorts, Fidson will gain from this partnership exclusive distribution rights to the internationally recognized immune therapy LodonalTM [Low Dose Naltrexone]. It is expected that such collaboration will bring global recognition to Fidson’s pharmaceutical enterprise. Dr. Fidelis Akhagboso Ayebae is Fidson’s Managing Director and Chief Executive Officer. During his twenty years, heading Fidson, he has turned his company into a leading Nigerian pharmaceutical company, which is publicly traded with annual US earnings of $60.5 million. This has made it one of the largest such pharmaceutical companies in Nigeria, and it has positioned it securely for global expansion.

“My goal,” Dr. Ayebae said, “is to provide Nigerians with affordable pharmaceuticals of excellent quality at affordable prices. I am very confident that working with USP will help me achieve this end.” !
To prepare for major growth, Dr. Ayebae has invested $55 million into building a six-line pharmaceutical manufacturing plant in Osun State, Nigeria [the largest and most expansive in all of Africa]. The new plant is expected to more than double production and expand Fidson’s outreach into Nigeria and Africa. Dr. Gloria B. Herndon, President and CEO of GB Pharma Holdings of Washington, DC, will assist in this growth. Positioned to provide affordable and sustainable healthcare solutions throughout Africa, she will be a behind-the-scenes catalyst that will offer specialized expertise and outreach into helping Fidson develop its pharmaceutical market.

“Our business arrangement will provide Dr. Ayebae with access to a variety of our products that are approved by the Nigeria’s National Agency for Food and Drug Administration and Control’s regulatory body,” Dr. Herndon said. “This includes the wonder drug LodonalTM discovered by Dr. Bernard Bihari in the 1980s. This low-dose Naltrexone has a proven to be a true wonder drug for combating HIV and other immune system diseases. This particular drug is not only innovative but it is also economically sustainable at about a $1 per day. As a result, we believe it will save many lives in Africa”
Doctors Herndon and Ayebae are both excited about their important business relationship. “Dr. Ayebae and I both share the same core values,” Dr. Herndon said. “He not only supports excellence, but he is also an ethical leader who has created a world-class company. His plant in Nigeria is the best I have ever seen in Africa – and even in the world. We both believe our union will contribute to strengthening the ties between the U.S. and Nigeria.

“How can we fail?” Dr. Herndon concluded. “It will be in the same spirt of collaboration that U.S. President Barack Obama and Nigerian President President Muhammadu Buhari have already discussed in the past.”

Photo Credit: Gustave Asiri

Categories: Local | News

Get the Los Angeles Sentinel App!


SEARCH:    

LA Sentinel
in your pocket:






TOS-Cookbook-Web
© 2017 Los Angeles Sentinel All Rights Reserved • A Bakewell Media Publication

Contact UsAboutMedia KitCorrections & Misprints

Terms of ServicePrivacy Policy

LA Watts TimesTaste of Soul

Close / I'm already on the list

Subscribe Today!

Don't be limited anymore! Subscribe Now »

** Existing subscribers, please Login / Register for Digital »

Subscribe to The Los Angeles Sentinel for only $5.99 $3.99 per month, with 1 month free!

Relax in comfort each week as you read the printed newspaper on your own time, delivered weekly to your home or office. This subscription also includes UNLIMITED DIGITAL ACCESS for all of your devices. Includes FREE shipping! One easy payment of $3.99/month gets you:

Subscribe Now »